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ntravascular Ultrasound Analysis of
olymer-Based Paclitaxel-Eluting Stents
ith great interest I read the report by Weissman et al. (1) regarding
ntravascular ultrasound (IVUS) analysis of polymer-based
aclitaxel-eluting stents. The investigators stated in the text that
positive remodeling assessed as the absolute increase in the
xternal elastic membrane volume over time tended to be slightly
ore prominent with the TAXUS stent (7.66  48.64 mm3 vs.
12.29  36.05 mm3, respectively, p  0.064).” Also Figure 1
uggested positive remodeling in the TAXUS stent. However,
able 2 of their article (1) shows an inconsistent result, that is,
ecrease of external elastic membrane volume in the TAXUS-stent
roup (283  91 mm3 at postimplantation vs. 280  89 mm3 at
ine-month follow-up). Because a previous IVUS analysis has also
uggested positive remodeling in the TAXUS stent (2), it may be
f great importance to better clarify this result.
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EPLY
e appreciate Dr. Kaneda’s astute observation about the data
ontained in our report (1) on the intravascular ultrasound (IVUS)
esults from TAXUS-IV. It is indeed true that there was a trend for
he vessel receiving a TAXUS stent to demonstrate positive remod-
ling, similar to prior drug-eluting stent (DES) reports. The analysis
or remodeling used only TAXUS and non-TAXUS patients with
omplete volumetric IVUS data of the external elastic membrane
EEM) throughout the stent length at both the time of stent
mplantation and at follow-up. As it states in the Methods section,
Volumes were calculated only if the vascular interface was visualized
very millimeter throughout the stent” (i.e., we did not extrapolate the
EM border for images in which it was not visualized). Thus, not all
atients with EEM volume data at stent implantation had EEM
olume data at follow-up, and vice-versa. Table 2 of the study (1)
eports all the volume data at one time point (postimplantation or
ollow-up) and the statistical analysis for change (and Figure 1 of the
eport [1] displaying change over time) used only patients that had taired postimplantation and follow-up EEM volume data. Hence, the
esults of a trend toward positive remodeling in the TAXUS stent are
ndeed accurate and in concordance with other DES studies.
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estenosis, Statistics,
nd Reasonable Inferences
e appreciate the accompanying editorial (1) to our recent report
ntitled “Relationship Between Angiographic Late Loss and Tar-
et Lesion Revascularization After Coronary Stent Implantation:
nalysis From the TAXUS-IV Trial” (2) but we wish to clarify
everal apparent misconceptions. Our principal messages are that
n the era of drug-eluting stents (DES), it is not only the mean
alue but also the shape of the distribution curve (variance and
kewedness) that will determine the population target lesion
evascularization (TLR), and that with a homogeneous response
n-stent late losses up to about 0.75 mm may provide acceptable
linical results (2). That DES may have rightward skewed late loss
istograms has been previously reported (3). The fact that the
ndividual patient late loss/TLR relationship is curvilinear with an
pparent inflection point, rather than linear, had not been reported
nd is a novel and unique observation that has since been replicated
n several other DES trials (DELIVER, ENDEAVOR-II). Most
mportantly, given the rightward skew in patient population data
een in all these trials (including the pivotal SIRIUS trial of the
irolimus-eluting stent), a certain lower level or “floor” of TLR
ay be unavoidable, somewhat independent of the mean late loss.
Moreover, recent data reported at the most recent American
ollege of Cardiology meetings substantiate our findings. The
NDEAVOR-II trial, with a considerably higher mean late loss
0.62 mm) but with rather a homogeneous effect (standard
eviation of late loss 0.46), reported a low TLR of 4.6% with the
BT-578-eluting stent. The large-scale REALITY trial, compar-
ng the sirolimus-eluting and paclitaxel-eluting stents, found
ignificantly greater in-stent late loss with the latter (0.09 vs. 0.31
m, respectively, p  0.001), but nearly identical eight-month
LR rates (5.0% vs. 5.4%, p  0.81). Thus, given the patient and
esion complexity studied in the pivotal DES trials to date, an
acceptable” TLR can be achieved with a relatively high in-stent
ate loss, providing that a homogeneous response is seen.
In addition, other variables beyond angiographic late loss that
ay affect TLR rates must be considered, including the inaccura-
ies and variability of quantitative measures of late loss. Variable
hresholds of patient angina perception, follow-up ischemia detec-
